1015787-98-0,MFCD24539325
Catalog No.:AA0004RL

1015787-98-0 | Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
95%
1 week  
$101.00   $71.00
- +
2mg
95%
1 week  
$119.00   $84.00
- +
5mg
95%
1 week  
$159.00   $112.00
- +
10mg
95%
1 week  
$204.00   $143.00
- +
25mg
95%
1 week  
$358.00   $251.00
- +
50mg
95%
1 week  
$543.00   $380.00
- +
100mg
95%
1 week  
$775.00   $543.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA0004RL
Chemical Name:
Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
CAS Number:
1015787-98-0
Molecular Formula:
C14H19N5O4S
Molecular Weight:
353.3968
MDL Number:
MFCD24539325
SMILES:
COc1cc(C(C)C)c(cc1S(=O)(=O)N)Oc1cnc(nc1N)N
Properties
Computed Properties
 
Complexity:
512  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0  
Rotatable Bond Count:
5  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
0.7  

Literature

Title: Medicinal chemistry of adenosine, P2Y and P2X receptors.

Journal: Neuropharmacology 20160501

Title: P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Journal: Lancet (London, England) 20150328

Title: Potential for developing purinergic drugs for gastrointestinal diseases.

Journal: Inflammatory bowel diseases 20140701

Title: The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.

Journal: Frontiers in cellular neuroscience 20130101

Title: Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7: 267.

Title: Ford AP, In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012 Feb;8(Suppl 1):3-26.

Title: Martin Nguyen A, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
Country:
Additional Info:
SDS
Related Products of 1015787-98-0
Tags:1015787-98-0 Molecular Formula|1015787-98-0 MDL|1015787-98-0 SMILES|1015787-98-0 Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
Catalog No.: AA0004RL
1015787-98-0,MFCD24539325
1015787-98-0 | Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
Pack Size: 1mg
Purity: 95%
1 week
$101.00 $71.00
Pack Size: 2mg
Purity: 95%
1 week
$119.00 $84.00
Pack Size: 5mg
Purity: 95%
1 week
$159.00 $112.00
Pack Size: 10mg
Purity: 95%
1 week
$204.00 $143.00
Pack Size: 25mg
Purity: 95%
1 week
$358.00 $251.00
Pack Size: 50mg
Purity: 95%
1 week
$543.00 $380.00
Pack Size: 100mg
Purity: 95%
1 week
$775.00 $543.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA0004RL
Chemical Name: Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
CAS Number: 1015787-98-0
Molecular Formula: C14H19N5O4S
Molecular Weight: 353.3968
MDL Number: MFCD24539325
SMILES: COc1cc(C(C)C)c(cc1S(=O)(=O)N)Oc1cnc(nc1N)N
Properties
Complexity: 512  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 24  
Hydrogen Bond Acceptor Count: 9  
Hydrogen Bond Donor Count: 3  
Isotope Atom Count: 0  
Rotatable Bond Count: 5  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 0.7  
Literature fold

Title: Medicinal chemistry of adenosine, P2Y and P2X receptors.

Journal: Neuropharmacology20160501

Title: P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Journal: Lancet (London, England)20150328

Title: Potential for developing purinergic drugs for gastrointestinal diseases.

Journal: Inflammatory bowel diseases20140701

Title: The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.

Journal: Frontiers in cellular neuroscience20130101

Title: Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7: 267.

Title: Ford AP, In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012 Feb;8(Suppl 1):3-26.

Title: Martin Nguyen A, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743.

Building Blocks More >
101622-51-9
101622-51-9
Ethanol, 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-
AA0004WG | MFCD00189360
1017606-58-4
1017606-58-4
(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate
AA0005C6 | MFCD18249855
10185-68-9
10185-68-9
4-(5-methyl-1,2,4-oxadiazol-3-yl)aniline
AA0005NT | MFCD08435856
101975-10-4
101975-10-4
3(2H)-Pyridazinone, 6-[4-(difluoromethoxy)-3-methoxyphenyl]-
AA00061Q | MFCD00867059
102016-58-0
102016-58-0
3-[4-(Methylsulfanyl)phenyl]acrylic acid
AA000699 | MFCD00266583
1020721-61-2
1020721-61-2
1-Methyl-1H-pyrazole-5-sulfonyl chloride
AA0006HC | MFCD09065021
10220-22-1
10220-22-1
1-(4-nitrophenyl)pyrrolidine
AA0006T4 | MFCD00020819
1023595-11-0
1023595-11-0
4-Boc-1-oxa-4,9-diazaspiro[5.5]undecane
AA000762 | MFCD11227066
1025113-78-3
1025113-78-3
Potassium 5-formylthiophene-2-trifluoroborate
AA0007JR | MFCD09800740
102636-82-8
102636-82-8
1-Propanaminium, 3-carboxy-2-(4-carboxy-1-oxobutoxy)-N,N,N-trimethyl-, inner salt, (2R)-
AA0007X2 | MFCD16036250
Submit
© 2017 AA BLOCKS, INC. All rights reserved.